MEDIPOST obtained 6 European patents concurrently on the cord technology of Alzheimer-type dementia treatment using cord blood stem cells.

The title of this patent is ‘Composition for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells, comprising a human umbilical cord blood-derived mesenchymal stem cell as an active ingredient’.

MEDIPOST obtained patent in major European countries comprising U.K., Germany, France, Italia, Spain, Swiss etc.

As this patented technology induces regeneration of damaged brain nerve cell, commercialization of this could make another step approaching to fundamental treatment of dementia.

This patent has already been registered in Korea as well as China, Hong Kong, Singapore, Australia, Mexico.

This patented technology is planned to be applied to Alzheimer-type dementia medicine ‘NEUROSTEM^®’ currently under development.